Application of NGS in Ascites Infection

Sponsor
The Second Affiliated Hospital of Chongqing Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05352152
Collaborator
(none)
50
1
9.8
5.1

Study Details

Study Description

Brief Summary

Liver cirrhosis is a common serious chronic disease. There are about 123 million patients with liver cirrhosis worldwide, and about 1 million people die of liver cirrhosis every year. The proportion of bacterial infection in hospitalized patients with liver cirrhosis is between 25% and 46%, among which spontaneous bacterial peritonitis (SBP) is the most common type of infection in patients with liver cirrhosis. After early and reasonable diagnosis and treatment, the mortality of cirrhotic patients with SBP can be reduced from more than 90% to about 20%. Therefore, rapid and accurate diagnosis is of great help to improve the prognosis of cirrhotic patients with SBP. However, at present, the traditional detection methods is time-consuming with a low detection rate, and can not detect intracellular bacteria and some other types of pathogens.

Next-generation sequencing (NGS) is a relatively new detection technology which can detect the nucleic acid sequence information in a high-throughput, large-scale way. It can detect the pathogens comprehensively, fast and accurately. In recent years, NGS has gradually transitioned from a research tool to a diagnostic method. Many studies have shown that NGS has better application value in bloodstream infections, ocular infectious diseases, central nervous system infectious diseases and respiratory infectious diseases. However, there is still a lack of research on the use of NGS for the detection of pathogenic microorganisms in ascites. Therefore, by comparing the next generation sequence (NGS) and traditional detection technology in the detection of pathogens in ascites, this study aimed to evaluate the value of NGS in the pathogenic diagnosis of ascites infection.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Next generation sequence

Detailed Description

This study is observational and approximately 50 subjects will be included according to inclusion and exclusion criteria. Patients who meet the inclusion and exclusion criteria, will be were collected a sufficient amount of ascites, and the collected ascites will be divided into four different groups. One group will be used as a control, and the other three groups will be centrifugated at different speeds. After centrifugation, the four groups of specimens will be tested by NGS to detect the pathogens. By comparing the detection rate of NGS test for concentrated samples and unconcentrated samples, and this study aims to observe whether centrifugation could increase the detection rate. By comparing the results of NGS and the results of traditional detection methods, this study also aims to explore the consistency between NGS and traditional detection methods, and whether NGS has higher detection rates.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Application of Next Generation Sequence in the Etiological Diagnosis of Abdominal Infection in Patients With Liver Disease
Actual Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Mar 25, 2023
Anticipated Study Completion Date :
Apr 25, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients with ascites infection

Patients who is confirmed with ascites infection or clinically diagnosed as ascites infection will be enrolled in this cohort.

Diagnostic Test: Next generation sequence
Next generation sequence will be used to detect the pathogens in ascites.
Other Names:
  • Traditional detection method
  • Outcome Measures

    Primary Outcome Measures

    1. Results of next generation sequence [within 10 days of patient enrollment in study]

      Pathogens detected by NGS

    2. Results of traditional detection methods [within 10 days of patient enrollment in study]

      Pathogens detected by traditional detection methods

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Willing and able to sign informed consent;

    2. Age ≥ 18 years old;

    3. Have full civil capacity;

    4. The amount of ascites is suitable for puncture;

    5. Ascites infection confirmed by clinical etiology test or clinically suspected ascites infection (such as elevated leukocyte count, elevated procalcitonin, abdominal inflammation indicated by imaging, etc.)

    Exclusion Criteria:
    1. Those who cannot cooperate with the test;

    2. Those whose samples cannot be obtained by puncture;

    3. The cause of ascites is clear;

    4. Those who are considered to be not suitable for this study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Second Affiliated Hospital of Chongqing Medical University Chongqing Chongqing China 400000

    Sponsors and Collaborators

    • The Second Affiliated Hospital of Chongqing Medical University

    Investigators

    • Study Director: Dazhi Zhang, M.D., The Second Affiliated Hospital of Chongqing Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    The Second Affiliated Hospital of Chongqing Medical University
    ClinicalTrials.gov Identifier:
    NCT05352152
    Other Study ID Numbers:
    • Zhangdz2022
    First Posted:
    Apr 28, 2022
    Last Update Posted:
    Aug 9, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 9, 2022